scholarly journals Biliary tract cancers: current knowledge, clinical candidates and future challenges

2019 ◽  
Vol Volume 11 ◽  
pp. 2623-2642 ◽  
Author(s):  
Noor-ul-Ain Tariq ◽  
Mairéad G McNamara ◽  
Juan W Valle
Keyword(s):  
Biliary Tract ◽  
Current Knowledge ◽  
Biliary Tract Cancers ◽  
Future Challenges

scholarly journals A Population-Based Retrospective Study of Biliary Tract Cancers in Alberta, Canada

2021 ◽  
Vol 28 (1) ◽  
pp. 417-427
Author(s):  
Carissa Beaulieu ◽  
Arthur Lui ◽  
Dimas Yusuf ◽  
Zainab Abdelaziz ◽  
Brock Randolph ◽  
...  
Keyword(s):  
Biliary Tract ◽  
Demographic Data ◽  
Performance Status ◽  
Single Agent ◽  
Eastern Cooperative Oncology Group ◽  
Intrahepatic Bile Duct ◽  
Population Based ◽  
Phase Iii ◽  
First Line ◽  
Biliary Tract Cancers

Background: Biliary tract cancers (BTC) are uncommon malignancies and are underrepresented in the literature. Methods: We performed a retrospective population-based review of adult patients with biopsy-confirmed BTC in Alberta from 2000 to 2015. Demographic data, risk factors, symptoms, treatment, and staging data were collected and analyzed. Survival analyses were completed. Results: A total of 1604 patients were included in our study, of which 766 (47.8%) were male. The median age at diagnosis was 68 (range 19–99). There were 374 (23.3%) patients with resectable tumors at diagnosis versus 597 (37.2%) with unresectable tumors. Of the patients, 380 (21.5%) received chemotherapy (CT) and 81 (5.0%) underwent radiation therapy. There was a clear trend with worsening stage and performance status associated with shorter median overall survival (OS). Ampulla of Vater tumors had the best median OS (25.69 months), while intrahepatic bile duct cancers had the worst (5.78 months). First-line palliative CT regimens included gemcitabine+cisplatin (OS 14.98 months (mo), n = 212), single agent gemcitabine (OS 12.42 mo, n = 22), capecitabine (OS 8.12 mo, n = 8), and capecitabine+gemcitabine (OS 6.93 mo, n = 13). Patients with advanced or metastatic disease who received first-line gemcitabine+cisplatin had a median OS of 11.8 months (n = 119). Conclusion: BTCs have poor survival. Worse outcomes occur in higher stage and poorer Eastern Cooperative Oncology Group (ECOG) performance status patients across all tumor subtypes. Tumor resectability at diagnosis was associated with better OS. Our study supports the use of gemcitabine+cisplatin as a combination first-line palliative CT, as patients treated in Alberta have a comparable OS to that reported in the ABC-02 phase III study.

scholarly journals Synergistic Combination of Cytotoxic Chemotherapy and Cyclin Dependent Kinase 4/6 Inhibitors in Biliary Tract Cancers

Hepatology ◽  
2021 ◽  
Author(s):  
Mansi Arora ◽  
James M. Bogenberger ◽  
Amro M. Abdelrahman ◽  
Jennifer Yonkus ◽  
Roberto Alva‐Ruiz ◽  
...  
Keyword(s):  
Biliary Tract ◽  
Cytotoxic Chemotherapy ◽  
Cyclin Dependent Kinase ◽  
Biliary Tract Cancers ◽  
Synergistic Combination

scholarly journals Gemcitabine, Cisplatin, and nab-Paclitaxel for the Treatment of Advanced Biliary Tract Cancers

JAMA Oncology ◽  
2019 ◽  
Vol 5 (6) ◽  
pp. 824 ◽  
Author(s):  
Rachna T. Shroff ◽  
Milind M. Javle ◽  
Lianchun Xiao ◽  
Ahmed O. Kaseb ◽  
Gauri R. Varadhachary ◽  
...  
Keyword(s):  
Biliary Tract ◽  
Biliary Tract Cancers

Addition of an antiangiogenic therapy, bevacizumab, to gemcitabine plus oxaliplatin improves survival in advanced biliary tract cancers

2017 ◽  
Vol 36 (1) ◽  
pp. 156-162 ◽  
Author(s):  
Marie Bréchon ◽  
Marie Dior ◽  
Johann Dréanic ◽  
Bertrand Brieau ◽  
Marie-Anne Guillaumot ◽  
...  
Keyword(s):  
Biliary Tract ◽  
Antiangiogenic Therapy ◽  
Biliary Tract Cancers

scholarly journals Adjuvant chemotherapy for resected biliary tract cancers: a systematic review and meta-analysis

HPB ◽  
2017 ◽  
Vol 19 (9) ◽  
pp. 741-748 ◽  
Author(s):  
Michele Ghidini ◽  
Gianluca Tomasello ◽  
Andrea Botticelli ◽  
Sandro Barni ◽  
Giampietro Zabbialini ◽  
...  
Keyword(s):  
Systematic Review ◽  
Adjuvant Chemotherapy ◽  
Biliary Tract ◽  
Meta Analysis ◽  
Biliary Tract Cancers

Current and emerging therapies for advanced biliary tract cancers

2021 ◽  
Vol 6 (11) ◽  
pp. 956-969
Author(s):  
Audrey E Kam ◽  
Ashiq Masood ◽  
Rachna T Shroff
Keyword(s):  
Biliary Tract ◽  
Biliary Tract Cancers ◽  
Emerging Therapies

scholarly journals Statin use and reduced risk of biliary tract cancers in the UK Clinical Practice Research Datalink

Gut ◽  
2018 ◽  
Vol 68 (8) ◽  
pp. 1458-1464 ◽  
Author(s):  
Zhiwei Liu ◽  
Rotana Alsaggaf ◽  
Katherine A McGlynn ◽  
Lesley A Anderson ◽  
Huei-Ting Tsai ◽  
...  
Keyword(s):  
Clinical Practice ◽  
Biliary Tract ◽  
Conditional Logistic Regression ◽  
Incidence Density ◽  
Practice Research ◽  
Clinical Practice Research Datalink ◽  
Biliary Tract Cancers ◽  
The Uk ◽  
Reduced Risk ◽  
Statin Use

ObjectiveTo evaluate the association between statin use and risk of biliary tract cancers (BTC).DesignThis is a nested case–control study conducted in the UK Clinical Practice Research Datalink. We included cases diagnosed with incident primary BTCs, including cancers of the gall bladder, bile duct (ie, both intrahepatic and extrahepatic cholangiocarcinoma), ampulla of Vater and mixed type, between 1990 and 2017. For each case, we selected five controls who did not develop BTCs at the time of case diagnosis, matched by sex, year of birth, calendar time and years of enrolment in the general practice using incidence density sampling. Exposures were defined as two or more prescription records of statins 1 year prior to BTC diagnosis or control selection. ORs and 95% CIs for associations between statins and BTC overall and by subtypes were estimated using conditional logistic regression, adjusted for relevant confounders.ResultsWe included 3118 BTC cases and 15 519 cancer-free controls. Current statin use versus non-use was associated with a reduced risk of all BTCs combined (adjusted OR=0.88, 95% CI 0.79 to 0.98). The reduced risks were most pronounced among long-term users, as indicated by increasing number of prescriptions (ptrend=0.016) and cumulative dose of statins (ptrend=0.008). The magnitude of association was similar for statin use and risk of individual types of BTCs. The reduced risk of BTCs associated with a record of current statin use versus non-use was more pronounced among persons with diabetes (adjusted OR=0.72, 95% CI 0.57 to 0.91). Among non-diabetics, the adjusted OR for current statin use versus non-use was 0.91 (95% CI 0.81 to 1.03, pheterogeneity=0.007).ConclusionCompared with non-use of statins, current statin use is associated with 12% lower risk of BTCs; no association found with former statin use. If replicated, particularly in countries with a high incidence of BTCs, our findings could pave the way for evaluating the value of statins for BTC chemoprevention.

Sign in / Sign up

Export Citation Format

Share Document